Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Dec 13, 2018

NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus MSCs in Patients with Osteoarthritis

Sep 19, 2018

Cynata’s Cymerus MSCs Ameliorate Cytokine Release Syndrome in Preclinical Study

See More Press Releases

The Conversation (0)

Alert Options

No alert set

INN Article Notification

Instant Daily Weekly

Alert Option

You will be notified when this event occurs. No additional settings needed.